FimmCyte

Description

FimmCyte develops targeted immunotherapies that recognize a fibrosis-associated protein to selectively eliminate diseased fibrotic tissue and modulate immune responses for treating endometriosis and other fibro-inflammatory conditions.

Related

• Cleara BiotechCleara Biotech develops peptide-based therapies that selectively eliminate p53-impaired cancer cells; products include lead development…
• Freya BiosciencesFreya Biosciences develops clinical-stage immunology therapies that target inflammation and immune dysregulation to treat women’s health…
• ImmaticsImmatics develops PRAME-targeted immunotherapies, advancing T-cell receptor cell therapies and bispecific molecules such as IMA203 and…
• Engimmune Therapeutics AGEngimmune Therapeutics AG engineers soluble T‑cell receptor (TCR) therapeutics using AI‑guided protein engineering to create multispecific,…
• Agomab TherapeuticsAgomab Therapeutics develops disease-modifying therapies for fibro-inflammatory conditions through TGFβ/ALK5 (TGFβR1) pathway targeting,…
• SciRhomSciRhom develops humanized antibodies against iRhom2 that selectively inhibit TACE in immune cells, blocking TNF-alpha, IL-6, and HB-EGF…
• ScientaLabScientaLab develops a foundation model that predicts human immune response in immunology and inflammation, using multi-disease,…
• TTolerogenixxTolerogenixx develops personalized therapies using proprietary modified immune cell technology to target immune modulation, including…
• CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…